A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome

Journal of Clinical Psychiatry

Volumn 70, Issue 10, 2009, Pages 1397-1406

  Weiden, Peter J ^a,b   Schooler, Nina R ^b   Weedon, Jeremy C ^c   Elmouchtari, Abdel ^b   Sunakawa, Ayako ^b   Goldfinger, Stephen M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Downstate Health Sciences University   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; STRUCTURED INTERVIEW;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 72849116914     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05284yel     Document Type: Article

References (29)

1. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479. PubMed doi:10.1176/appi.ajp.161.3.473 (Pubitemid 38326102)
2. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. PubMed doi:10.1176/appi.ajp.164.7.1050
3. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive firstepisode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995-1003. PubMed
4. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. PubMed doi:10.1016/S0140-6736(08)60486-9
5. Velligan DI, Lam F, Ereshefsky L, et al. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54(5):665-667. PubMed doi:10.1176/appi.ps.54.5.665
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry. 2004;161(suppl 2):1-56. PubMed
7. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193-217. PubMed
8. Kane JM, Leucht S, Carpenter D, et al. The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19. PubMed
9. Weiden PJ, Preskorn SH, Fahnestock PA, et al. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J Clin Psychiatry. 2007;68(suppl 7):1-48. PubMed
10. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 1999;60(10):649-657. PubMed
11. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed
12. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201-208. PubMed doi:10.1016/0920-9964(92)90003-N
13. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM)76-338. Rockville, MD: National Institute of Mental Health; 1976:217-222.
14. Schooler NR, Chengappa KNR. Adverse effects measures. In: American Psychiatric Association Task Force for the Handbook of Psychiatric Measures, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:151-168.
15. Barnes TR. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol. 2003;17(4):365-370. PubMed doi:10.1177/0269881103174013
16. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;45(suppl 212):11-19. doi:10.1111/j.1600-0447.1970. tb02066.x
17. Sunakawa A, Weiden P, Weedon J, et al. Adherence outcomes in schizophrenia trials: advances in measuring time until discontinuation [presented at the 48th Annual NCDEU Meeting: New Research Approaches for Mental Health Interventions]. In: Poster Abstracts of the 48th Annual NCDEU Meeting: The Art and Science of Personalizing Treatments for Mental Disorders; May 27-30, 2008; Phoenix, AZ. Session II-65:147.
18. Weiden P, Rapkin B, Mott T, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20(2):297-310. PubMed
19. Tunis SL, Faries DE, Stensland MD, et al. An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia. Curr Med Res Opin. 2007;23(1):97-104. PubMed doi:10.1185/ 030079907X162665
20. Patel MX, De Zoysa N, Bernadt M, et al. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry. 2008;69(10):1548-1556. PubMed
21. Patel MX. De Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12(2):237-244. PubMed doi:10.1111/j.1365-2850.2004.00826.x (Pubitemid 40515360)
22. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003;33(1):83-89. PubMed doi:10.1017/S0033291702006797 (Pubitemid 36113403)
23. Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210-213. PubMed doi:10.1097/JCP. 0b013e318167269d
24. Craig TK, Garety P, Power P, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004;329(7474):1067. doi:10.1136/bmj.38246.594873.7C (Pubitemid 39490685)
25. Addington J, Leriger E, Addington D. Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry. 2003;48(3):204-207. PubMed (Pubitemid 36596949)
26. Malla A, Norman R, Bechard-Evans L, et al. Factors influencing relapse during a 2-year follow-up of firstepisode psychosis in a specialized early intervention service. Psychol Med. 2008;38(11):1585-1593. PubMed doi:10.1017/S0033291707002656
27. Petersen L, Thorup A, Øqhlenschlaeger J, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry. 2008;53(10):660-670. PubMed
28. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry. 1980;37(1):16-24. PubMed (Pubitemid 10139118)
29. Mentschel CC, Leucht SM, Kane JM. Depot-drugs may reduce relapses in schizophrenic outpatients: a meta-analysis [presented at the 156th Annual Meeting of the American Psychiatric Association]. In: New Research Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA. Abstract NR191:71.